Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexFemale
Age18+
SponsorSun Yat-sen University
About this trial
This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.
Eligibility criteria
Qualifiers
Women aged 18 years and above with pathologically confirmed recurrent or metastatic advanced breast cancer ;
The patient has tumor specimens (formalin-fixed, paraffin-embedded or fresh pre-treated recurrent tumor tissue);
Patients who have failed standard treatment in the late stage;
At least one measurable lesion;
Disqualifiers
Patients with acute active hepatitis B or acute active hepatitis C;
Any serious underlying disease, comorbidity and active infection
Currently receiving other anti-tumor treatments;
History of epilepsy or epileptic-induced condition;
Trial design
Treatments tested in this trial
- Bortezomib (B)
- Cisplatin (CDDP)
- Bortezomib (B)
- Bortezomib (B)
- Cisplatin (CDDP)
Treatment groups
20 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov